26
Participants
Start Date
January 2, 2008
Primary Completion Date
September 25, 2012
Study Completion Date
February 13, 2015
irinotecan hydrochloride
In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
olaparib
In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
Ottawa Health Research Institute - General Division, Ottawa
Univ. Health Network-Princess Margaret Hospital, Toronto
Lead Sponsor
Collaborators (1)
AstraZeneca
INDUSTRY
NCIC Clinical Trials Group
NETWORK